Aditxt, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219
Mailing Address 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219
Phone 909-488-0844
Fiscal Year End 1231
EIN 823204328
Financial Overview
FY2025
$23.86M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | December 19, 2025 | View on SEC |
Annual Reports
10-K March 31, 2026
- Developing innovative ADI™ technology to retrain the immune system for organ transplants and autoimmune conditions.
- Pearsanta subsidiary advancing early-stage diagnostic tests for prostate cancer and endometriosis using Mitomic® technology.
Material Events
8-K Financial Distress March 13, 2026
High Impact
- Acquired Ignite Proteomics, LLC, expanding capabilities in advanced proteomics and precision medicine.
- Successfully addressed Nasdaq delisting threat by boosting stockholders' equity to an estimated $37.5 million.
8-K Financial Distress February 13, 2026
High Impact
- Shareholders authorized the board to implement a reverse stock split (1-for-5 to 1-for-250) to meet NASDAQ listing requirements.
- Approval for issuing common shares to fulfill past funding agreements, converting preferred stock and warrants.
8-K Strategy Change January 30, 2026
High Impact
- Seeking to maintain NASDAQ listing compliance through a reverse stock split.
- Proposing a potential strategic rebranding and pivot with a name change to 'bitXbio, Inc.'
8-K Financial Distress January 28, 2026
High Impact
- Aditxt secured a Nasdaq extension, providing a conditional lifeline to regain compliance with listing standards.
- The company has submitted a plan to Nasdaq focusing on completing financing transactions to bolster its capital base and improve stockholders' equity.
8-K Financial Distress December 5, 2025
High Impact
- Aditxt, Inc. received a notice from Nasdaq for failing to meet Listing Rule 5550(b)(1), as its stockholders' equity fell below the required $2.5 million minimum.
- The company faces potential delisting from Nasdaq if it cannot regain compliance with the financial requirement.
Insider Trading
SELL 2 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
NERVGEN PHARMA CORP.
NGEN Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB Pharmaceutical Preparations
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV
HURA Pharmaceutical Preparations
Canton Strategic Holdings, Inc.
CNTN Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.